Herbalife Ltd. — FY2023 Form 10-K
Business context and reporting period. This is the annual report for the fiscal year ended December 31, 2023, not a standalone Q4 report. Herbalife sells nutrition and wellness products through independent members in 95 markets. Formula 1 was approximately 26% of annual net sales; weight-management products represented 56.3% of sales. The company reported approximately 6.5 million Members at year-end.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Net sales | $5,062.4 million | $5,204.4 million |
| Gross profit / margin | $3,871.4 million / 76.5% | $4,030.8 million / 77.4% |
| Operating income / margin | $356.4 million / 7.0% | $545.2 million / 10.5% |
| Net income | $142.2 million | $321.3 million |
| Diluted EPS | $1.42 | $3.23 |
| Operating cash flow | $357.5 million | $352.5 million |
| Cash and cash equivalents at year-end | $575.2 million | $508.0 million |
| Working capital at year-end | $121.7 million | $379.5 million |
| Total debt carrying value | $2,562.4 million | $2,692.0 million |
Net sales declined 2.7% in U.S. dollars and 1.6% in local currency. Worldwide Volume Points, management’s sales-volume indicator, fell 9.1%. Price increases contributed an 8.5% favorable impact, partly offsetting lower volume, unfavorable currency translation, and sales mix. Net income fell 55.7%. Gross margin declined 98 basis points; operating margin fell 350 basis points. Net interest expense increased to $154.4 million from $133.2 million, and the effective tax rate rose to 30.0% from 24.4%.
Investing cash outflow was $134.8 million; cash purchases of property and equipment were $135.0 million. Working capital decreased by $257.8 million, reflecting higher current debt—principally the 2024 convertible notes becoming due—and other current liabilities. The company reported compliance with debt covenants and approximately $285 million of available revolver capacity. It expects a $66.1 million mandatory Term Loan B prepayment in Q1 2024. Variable-rate credit-facility borrowings carried a 7.62% weighted-average rate at year-end, versus 4.08% a year earlier.
Material changes and management commentary
- Regional sales were mixed: North America fell 10.4%, China fell 16.3%, EMEA fell 0.9%, Latin America rose 4.5%, and Asia Pacific rose 1.6%. India sales increased 17.6%; U.S. sales declined 10.2%.
- Management attributed volume weakness to fewer new Members, Member transitions back to in-person selling, inflation and economic pressure, and market-specific factors. Mexico import-permit delays affected some inventory and sales late in the year.
- Cost of sales rose as a share of revenue, with higher raw-material, manufacturing-labor, and allocated overhead costs, partly offset by price increases. SG&A increased 3.1% to $1,866.0 million.
- The company recorded $54.2 million of Transformation Program expenses and $32.1 million of Digital Technology Program expenses. It also recorded an $8.6 million Korea customs-duty settlement expense and a $1.0 million gain on extinguishment of convertible notes.
Outlook, risks, and contingencies
- Management expects 2024 capital expenditures of approximately $145 million to $195 million, including Herbalife One investments. It expects about $30 million of non-cash amortization expense in 2024 related to Herbalife One; additional annual amounts may vary.
- The Transformation Program is expected to be completed in 2024. Management estimates at least $115 million of annual savings, with approximately $70 million realized in 2023 and approximately $115 million expected in 2024 and thereafter; estimated total pre-tax program costs are at least $95 million.
- Management states that operating cash flow, available credit, and capital-market access should fund operations, planned investment, and foreseeable liquidity requirements. Refinancing options for the senior secured credit facility are being assessed.
- Debt maturities and funding remain important: $197.0 million principal of 2024 convertible notes was outstanding at year-end and matured March 15, 2024; $600 million of 7.875% senior notes mature in September 2025. The company did not pay cash dividends in 2023 and has not paid them since 2014.
- Key risks include reliance on Members and the direct-selling model, regulatory scrutiny and FTC Consent Order compliance, product and advertising regulation, dependence on Formula 1, foreign exchange and international operations, China-specific regulation, cybersecurity, supply-chain and inflation pressures, and debt covenants and refinancing.
- Contingencies include tax disputes in Brazil, India, and Mexico; the company says losses are not considered probable for many disputed assessments, but outcomes and potential amounts are uncertain. Mexico had $22.6 million of VAT-related assets, which management believes recoverable. A Korea customs settlement was recorded in 2023. The Rodgers class action settlement received final approval and was funded with $12.5 million in escrow. The company says it believes it fulfilled its SEC/DOJ FCPA agreement obligations; the DOJ deferred-prosecution term expired in August 2023, with dismissal dependent on DOJ’s determination of compliance.
- The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal financial controls were effective at year-end.
Most important facts for investors to verify
- Whether volume and Member recruitment stabilize, particularly in North America and China, and whether price increases can be sustained without further demand erosion.
- Progress on 2024 convertible-note maturity and credit-facility refinancing, the $66.1 million mandatory prepayment, debt covenants, and borrowing costs.
- Actual Herbalife One and Transformation Program spending, timing, savings, and expected amortization compared with management estimates.
- Developments in tax assessments and refunds, including Mexico VAT recoverability and Brazil and India disputes, as well as final resolution of the DOJ deferred-prosecution matter.
- Whether the company’s cash generation and available liquidity remain adequate amid lower sales, elevated investment needs, and substantial debt.